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Mainly elderly people with pale skin are affected by actinic keratoses (AK). Due to the demographic change, the prevalence 
of AK increased over the last years. An established risk factor is chronic UV-exposure (outdoor workers) inducing mutations 
of the tumor suppressor gene TP53 and the oncogene H-Ras. This leads to an intraepidermal proliferation of atypical 
keratinocytes. The term “field cancerization” characterises the presentation of multiple AK in UV-exposed areas. AK are also 
termed squamous cell carcinoma (SCC) in situ. The risk for AK turning into a SCC is 6—10%. In order to avoid invasive 
growth, an early treatment is recommended. During the last years multiple therapeutic options have been established. 
Depending on the clinical extent, lesion- or field-directed therapies with excellent clinical response and cosmetic results are 
available.
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 The disease pattern of actinic keratoses (AK) was 
first described by freudenthal in 1926. In 1958, the term 
„actinic keratoses“ was mentioned by Pinkus for the first 
time [1]. chronic uV radiation leads to a proliferation of 
atypical keratinocytes in the basal layer of the epidermis, 
wherefore AK are also termed squamous cell carcinoma 
(Scc) in situ. The incidence of AK increased significantly 
over the last years. In the daily routine of a dermatologist 
the treatment of AK is one of the most frequent tasks.
Epidemiology
AK are predominantly found in patients with pale 
skin, blue eyes and red hair (fitzpatrick skin types I/II). 
The risk of getting AK is significantly (40%) increased 
in patients who sunburn more easily than in individuals 
with brown hair and eyes [2, 3, 4]. The prevalence of 
AK reaches 6—15% in the European population over 
the age of 40. There is gender predominance; men are 
significantly more often affected. The prevalence is also 
age-related, it increases with higher age and represents 
20% in 60 year-old individuals and 52% by the age of 
70 [2]. In summary, a significant increase of AK during 
the last 10 years was noticed. cause of this increment 
is the demographic change with many elderly people [3]. 
Outdoor workers with high uV exposure demonstrate 
significantly more AK than people working in an office 
[5—7]. Other risk factors include organ transplantation 
and/or chronic immunosuppression. After 20 years of 
immunosuppression the risk of getting AK is 40—60% 
with a high tendency to malignant transformation into 
squamous cell carcinoma [8].
Pathogenesis
The prevalence of AK is linked to chronic uV exposure, 
especially uVB radiation [5—11]. uV radiation leads to a 
mutation of the tumor suppressor gene TP53. This gene 
is located at chromosome 17p13.1 coding for the protein 
p53. p53 is an important regulator of the cell cycle, induc-
ing apoptosis of mutated cells. uV-radiation causes the 
„uV-typical“ signature change from cytidine to thymidine in 
TP53. This leads to an inactivation of TP53, which results 
in an uncontrolled proliferation of genetically unstable ke-
ratinocytes and development of AK [9—11].
furthermore, uV radiation leads to a mutation in co-
don 12 of the Ras-oncogene H-Ras, which is an important 
regulator of the Erk1/Erk2-pathway, regulating the prolifer-
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ation of cells. As a consequence of the mutation, the path-
way is permanently activated, also resulting in an uncon-
trolled cell proliferation. This mutation was also detected 
in non melanoma skin cancers (NMSc) like AK and Scc 
(figure 1) [12, 13]. In melanoma patients with metastatic 
disease and therapeutic intervention with the so-called 
BRAf-inhibitors, a significant side effect is the develop-
ment of NMSc, based on the iatrogenic imbalance in the 
generation of those tumors via an activation of the H-Ras 
pathway [14].
Repeatedly discussed is an association of AK respec-
tively Scc and infections with human papilloma virus 
(HPV). zaravinos et al. detected HPV-DNA by PcR in 31% 
of the investigated AK and in 33% of the investigated Scc 
[15]. Other analyses showed significantly higher levels of 
viral load in AK compared to Scc and normal skin. [16]. 
In conflict with these results are observations showing that 
HPV-DNA is also detected on normal skin and in hair fol-
licles and therefore should probably only be seen as a co-
incidal connection [17]. 
Clinical aspects
AK are often detected in sun exposed areas of elderly 
people like the scalp, forehead, bridge, ear helices, cheek, 
forearm and dorsum of the hand. In many cases more AK 
are observed in the left face, probably due to uV trans-
mission of window glass of the side windows in cars. AK 
become clinically manifest as isolated, about 0,1—2,5 cm 
sized circumscribed, skin-coloured, erythematous, occa-
sionally pigmented, scaly and rough plaques, sometimes 
with crusting and hyperkeratoses (figure 2). usually AK are 
symptomless. In rare cases they appeare with itching and 
burning [9]. AK localised in the area of the lower lip are 
rare and termed „cheilitis actinica“. “field cancerisation” is 
a confluence of isolated AK in different stages. [18]. Due to 
the variable clinical appearance of AK, 4 clinical subtypes 
are defined:
  erythematous type
  keratotic type
  pigmented type
  Lichen-planus type
Fig. 1. Step-by-step model of the molecular pathogenesis of squamous cell carcinoma
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Fig. 2. 
Typical AK at the right temple in a 72-year 
old patient: not sharply defined edges, er-
ythematous, nonhyperkeratotic plaque
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morphic keratinocytes with large cell nuclei and little cy-
toplasm are found in the lower part of the epidermis. 
These atypical keratinocytes can be found throughout 
the whole epidermis during the developmental stages of 
an AK. furthermore, mitotic figures and dyskeratotic cells 
are observed. This picture is often accompanied by solar 
elastosis and occasionally by a dense infiltration of lym-
phocytes (figure 3). Depending on the degree of severity of 
the epidermal changes, AK can be divided into three his-
tological grades (AK I—III), analogous to the classification 
of cervical intraepithelial neoplasia (table) [20]. further-
more, several histological subtypes of AK also exist, and 
there is a differentiation between pigmented, akantholytic, 
bowenoid, lichenoid and hypertrophic actinic keratoses. 
Since there are no cytological differences between AK and 
Scc, AK can also be considered as squamous cell carci-
noma in situ. [21]. If there is infiltration or penetration of the 
basal layer of the epidermis by atypical keratinocytes, the 
lesion is called squamous cell carcinoma [9, 22, 23].
Prognosis
Data about the progress of Scc from AK vary widely 
and are specified with 0 — 0.53% per year [24]. Accord-
ing to Marks et al., the risk for an isolated AK turning into 
a squamous cell carcinoma is 0.24%. Since most patients 
have many actinic keratoses, the risk of developing at least 
one Scc within 10 years is estimated with 6.1 — 10% [25, 
26]. further investigations, however, expect an average pro-
gression within 2 years. Age and gender differences as well 
as localization of AK play no role regarding the progress of 
Scc [27]. However, the risk of progression is significantly 
higher in immunocompromised patients after organ trans-
plantion (8). In contrast, in approximately 15 — 63% cases 
a spontaneous remission of the AK can be seen, which also 
accounts for high clearance rates of AK in placebo groups 
in randomized controlled trials [24, 25].
Therapy
Due to the risk of progress into Scc, treatment of AK 
is recommended in every case. A variety of therapeutic op-
tions are available and the optimal therapeutic approach 
must be individually adapted to the patient. In principle, 
there is a choice between a lesion-directed therapy as 
treatment for isolated AK and a field-directed approach. 
The latter includes the treatment of multiple lesions and 
large areas (field-cancerization) [28]. In addition, physical 
therapy (see below) can be distinguished from immuno-
Fig. 3. 
Histopathological findings: atrophy of the 
epidermis, pleomorphic keratinocytes in 
the lower 2/3 of the epidermis (equiva-
lent to a AK II), subepidermal lymphocytic 
inflammatory infiltration as well as pro-
nounced solar elastosis
Table Histological degrees of severity of actinic keratoses (after Röwert-Huber [20])
AK I Atypical keratinocytes in the lower third of epidermis
AK II Atypical keratinocytes in the lower 2/3 of the epidermis
AK III Full enforcement of the whole epidermis with atypical keratinocytes
Diagnosis
AKs are diagnosed due to the clinical appearance and 
the tactile result. Dermatoscopy or confocal scanning laser 
microscopy (cSLM) can be helpful in unclear cases or in 
pigmented lesions. In case of very hyperkeratotic AK, a bi-
opsy is recommended to exclude the presence of a Scc 
[9, 19]. 
Differential Diagnoses
Differential diagnoses of AK are skin tumors like super-
ficial basal cell carcinoma, Bowen’s disease, Scc, lentigo 
maligna and seborrhoeic keratoses as well as dermatoses 
like psoriasis vulgaris, tinea corporis, seborrhoeic eczema 
and lichen planus. Another important differential diagnosis 
of AK mainly in the area of the lower leg is porokeratosis 
and has to be excluded by biopsy. 
Histopathology
The histological picture is characterized by a change 
of ortho- and parakeratosis. The epidermis may appear 
akanthotic widened or atrophic. In addition, atypical pleo-
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modulating and chemical therapies (figure 4). combina-
tions of therapies are also well established, especially in 
refractory cases. In addition to an adequate therapy pa-
tients should be informed of the positive effect of a con-
sistent uV protection. A study could show that regular ap-
plication of sunscreen in organ transplant patients reduced 
the formation of new AK lesions as well as the progression 
of AK to squamous cell carcinoma [29].
Lesion-directed therapeutic options 
Physical Therapy
One domain of the treatment of isolated AK are physi-
cal therapy options like cryosurgery, excision and curettage, 
which can be applied quickly and easily. However, these 
procedures seem to be less effective than drug therapies. 
This circumstance is based on the fact that only a few stud-
ies exist for the above mentioned therapies. Due to the high 
cost for the planning and conduct of a clinical trial no spon-
sor will be interested in the evaluation of these old proce-
dures. One exception is cryosurgery. This procedure is of-
ten used as a comparator in numerous controlled, random-
ized studies, because a lot of information regarding effectiv-
ity, sustained yield and cosmetic outcome are known [30].
Cryosurgery
cryosurgery represents a simple, effective, and eco-
nomic therapeutic option for isolated, thin AK. The treat-
ment with liquid nitrogen, either as a spray or as contact 
procedure, leads to an intracellular ice crystal formation 
followed by destruction of the cell organelles. In conse-
quence, tissue destruction also induces inflammatory 
and immunological responses [31]. Since the implemen-
tation of cryosurgery, with respect to temperature, dura-
tion, repetition, and distance, is not standardized, suc-
cess rates depend on the experience of the performing 
physician [18, 31]. Thai et al. showed that the freezing 
time correlates directly with the effectiveness. Only 39% 
of AK displayed a complete clinical healing after 5 sec-
onds of treatment, while freezing times > 20 seconds led 
to a complete remission in 83% of the lesions [32]. Data 
on response rates differ in the literature because of the 
many treatment-related variables and range between 39 
to 88% [31—34]. Main disadvantages are the painful-
ness of the procedure, local inflammatory reactions and 
permanent hypopigmentation due to the concomitant de-
struction of melanocytes [31—34]. Therefore cryosurgery 
is suitable only for lesion-directed therapy of isolated mild 
to moderate AK lesions. Both the cosmetic results after 
Fig. 4. Pathogenesis-oriented therapeutic approaches in AK
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cryosurgery and the patient satisfaction are inferior to the 
results of photodynamic therapy [34].
Laser ablation
Ablative laser procedures with the cO2 or Er:yAG la-
ser are alternative therapeutic options for mild and mod-
erate isolated AK. The therapeutic options are related 
with a temporary complete clinical healing of 90% [35]. 
furthermore, there are only a few studies with small num-
bers of patients, so that the statement is restricted [18]. 
Atypic keratinocytes in adnexal structures are not caught 
by laser ablation and are the origin of clinical relapse. 
Disadvantages of this treatment are again the tender-
ness, risk of infection and possible scarring in cases of 
aggressive ablation. Additionally, laser treatment does 
not have the possibility of a dermatohistopathological re-
port, so that laser ablation can be considered to be in an 
inferior position compared to surgical intervention in un-
clear cases [9, 18, 35].
Classical excision, curettage/shave biopsy
In addition to the classical excision, curettage and 
shave biopsy represent further treatment options, espe-
cially in cases of hypertrophic AK with the risk of already 
existing invasion in the corium. The advantage of this 
method is the possibility of a dermatohistopathologic eval-
uation and should be preferred to conservative treatment 
options in uncertain cases [9]. A statement regarding the 
effectiveness of surgical procedures cannot be established 
because there are no studies available also not with com-
parison to topical medication procedures [18]. Disadvan-
tage of this treatment is also the need for a local anesthe-
sia, as well as the risk of possible infections, scarring and 
hypo- or hyperpigmentation [9].
5-Fluorouracil + salicylic acid
A combination of 0.5 % 5-fluorouracil and 10% sali-
cylic acid (5-fu/SA) in the form of a laquer (Actikerall®) 
is approved since 2011 for the treatment of mild to mod-
erately thick, hyperkeratotic AK [18]. 5-fluorouracil in-
hibits as cytostatic agent DNA synthesis and thus the 
cell division [9, 36]. Salicylic acid acts as keratolytic, 
therefore the combined formulation is considered to be 
superior to other therapeutic options, in particularly in 
the treatment of hyperkeratotic AK [36]. The treatment 
should be given once daily for 6—12 weeks. Because 
of the application with the help of the brush a targeted 
treatment of individual AK is possible. A complete clini-
cal response could be reached in 55.4%, while 70% of 
these targeted areas showed a complete histological re-
sponse [36]. Side effects like itching and burning of the 
treatment area as well as mild to moderate local inflam-
matory reactions appeared 6 weeks after start of treat-
ment in >70% of the patients. These are usually limited 
to the application site, so that the therapy is overall well 
tolerated by the patients [36].
Lesion-directed photodynamic therapy 
The treatment of AK by photodynamic therapy (PDT) 
with a 5-aminolevulinic acid containing solution (Levu-
lan® Kerastick, DuSA) is approved in the uSA since 2002 
[9, 18]. Since 2003, 5-ALA methyl ester (Metvix®, Gal-
derma) as a cream is commercially available for the treat-
ment of AK, nodular and superficial basal cell carcinomas, 
and Bowen’s disease. A 5-ALA-containing gel (Ameluz®, 
Biofrontera) is registered since 2012 for the treatment of 
AK. The above mentioned preparations are suitable for 
the treatment of single AK and field-cancerisation. Since 
2010, there is also an adhesive patch (Alacare®, Galder-
ma) available, which contains 8 mg 5-aminolevulinic acid. 
with a size of 4 cm2 it is particularly suitable for treatment 
of individual lesions. without any pre-treatment the patch 
Fig. 5. 
Same patient as in Figure 2. Fluorescence 
diagnostics after 4-hour incubation with 
5-ALA-containing patch before light ex-
posure. Increased fluorescence in the AK-
area as an indicator for the preferential 
protoporphyrin-IX synthesis
Fig. 6. 
76-year-old patient. Side effects 2 days af-
ter PDT with the 5-ALA-containing patch. 
Redness and crusting are limited to the 
applied patch localization
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is directly applied to the lesions. The incubation period of 
4 hours is followed by illumination with red light (630 nm, 
37 j/cm2 [18, 37, 38]. In a double-blind comparative clini-
cal trial it could be shown that the effect of a patch-PDT 
is significantly superior to cryosurgery (clinical response 
rates after 12 weeks: 82—89% vs. 77%) and results in sig-
nificantly better cosmetical outcomes. In particular, postin-
flammatory hyperpigmentation was hardly observed after 
PDT [38]. further advantage is the possibility of a targeted 
treatment with significantly less pain during the exposure 
time. Side effects, such as redness, blisters and crusting 
occur in usually 1—2 days later and are limited to the ap-
plied patch localization (figure 5 and 6) [22, 37, 38].
Field-directed therapy
uV-induced mutations of keratinocytes exist in the 
whole uV-exposed area and are not strictly limited to vis-
ible AK lesions. Therefore development into AK also in 
this areas is very likely, although exact figures cannot be 
given. So the use of preparations or procedures which al-
ready target incipient AK would be beneficial to avoid the 
development of new AK at least for a certain amount of 
time. This concept is confirmed by multiple field-directed 
therapy options.
Hyaluronic acid gel diclofenac sodium
The product Solaraze® (Almirall) contains 3% diclof-
enac sodium and hyaluronic acid in a gel matrix and is 
registered for the use in AK since 2001. The exact mecha-
nism of action is not completely understood. It is assumed 
that an inhibition of the arachidonic acid pathway occurs 
by inhibition of the enzyme cyclooxygenase I and II (cOX I 
and II). This results in an inhibition of cell proliferation and 
angiogenesis [9, 18]. Applied twice daily for 90 days, the 
treatment leads to a remission rate of 40% [39]. Adverse 
reactions such as itching, burning, redness, and flaking 
are usually rare, so this therapy can be considered as be-
ing well tolerated by the patients [9, 40]. The treatment pe-
riod of 3 months is relatively long. However, an extension 
of the treatment period up to 6 months does not lead to an 
improvement of the effectiveness [9, 39].
Imiquimod
Imiquimod as an immunomodulator and strong inter-
feron-inducer is now available in three different concentra-
tions for the treatment of AK. Information respecting the 
response rates of the 5% preparation (Aldara®, Meda) in 
mild to moderate AK differs, depending on the regimen 
between 45% and 55% [41—43]. currently, a treatment 
3x/week for 4 weeks is recommended. After a 4-week in-
terval a second cycle can be performed [41]. In the lower 
concentration of 3.75% (zyclara®, Meda) Imiquimod is ap-
plied once daily for 2 weeks and is followed by another 
2-week-cycle after a 2-week treatment-free interval. The 
response rates are approximately 35% [44]. Studies have 
shown that a longer application interval does not lead to a 
better response rate [45]. A further 2.5% concentration of 
Imiquimod is marketed under the same name in the uS. 
Two well-controlled studies showed a similar response 
rate of the 2.5% formulation in comparison to the 3.75% 
cream (complete clearance 30.6% vs. 35.6%). Both im-
iquimod creams (2.5% and 3.75%) were significantly more 
effective than placebo [46]. Side effects such as redness, 
erosion and crusting occur in almost all cases, but are 
more likely to be seen in the higher concentrations of im-
iquimod. It may also come to flu-like symptoms in all con-
centrations [45]. Due to the concentration-dependent ad-
verse reactions, imiquimod 5% should be applied only in 
a maximum of 25 cm2 large area while imiquimod 3.75% 
is approved for the treatment of the entire scalp. However, 
the negative impact of the treatment is in particular the 
partly pronounced local reactions with the systemic side 
effects (figure 7). Therefore, a detailed investigation of the 
patients is essential to avoid discontinuation of treatment. 
The use of imiquimod in patients with autoimmune disease 
and transplant recipients under constant immunosuppres-
sion should be avoided due to the risk of immunological 
effects induced by the interferons.
Fig. 7. 
72-year old patient. Haemorrhagic-en-
crusted local reaction restricted in areas 
with existing AK after application with Im-
iquimod 5%
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Ingenol mebutate
Ingenol mebutate, a tri-terpene isolated from the 
sap of Euphorbia peplus, is registered in Europe since 
2013 for the treatment of AK in an area of 25 cm2. In the 
face and scalp, a treatment for 3 consecutive days with 
0.015% ingenol mebutate gel is recommended, while in 
the area of the trunk and the extremities the treatment 
should be performed on 2 consecutive days with a higher 
gel concentration of 0.05%. Placebo-controlled studies 
demonstrated response rates (complete clinical remis-
sion) of 42.2% in the face and scalp and 34.1% on the 
trunk, as well as the extremities after 8 weeks. A partial 
response was reached in 63.9% in the face and scalp 
and in 49.1% in the trunk and the extremities [47]. Over 
a follow up period of 12 months, 87% showed a persis-
tent clinical clearance [47, 48]. Side effects like local skin 
reactions, characterized by erythema, edema, blisters, 
crusts and pustules appeared 4 days after treatment start. 
In addition, patients complain about itching, burning and 
pain. Typically, the side effects subside within 2 weeks. 
In some rare cases hyperpigmentations can persist over 
months [47]. Advantage of the treatment with ingenol 
mebutate is the very short treatment period of 2 or 3 con-
secutive days with a subsequent, although pronounced, 
but time-limited inflammatory response. The currently 
available data relate to a treatment area of 25 cm2. Due 
to the time lag of the local reaction, a good education of 
the patient is required. At the moment, other clinical tri-
als comparing ingenol mebutate with other therapies are 
in progress. Ingenol mebutate 0,015%, applied 3 weeks 
following cryosurgery for 3 consecutive days, leads to a 
higher AK clearance rate than cryosurgery alone after 
11 weeks and reduces the appearance of new AK lesions 
after 12 months [49, 50].
5-Fluorouracil
In a concentration of 5% is 5-fluorouracil (Efudex®) ap-
proved since 1968 for NMSc treatment in large areas in-
cluding AK. A controversial issue is the application interval 
of 5% fluorouracil. jury et al. were able to show that an ap-
plication twice daily for 3 weeks leads to a much better re-
sponse than a once weekly application for 12 weeks [51]. 
Remission rates after 4 weeks application were 43% [52]. 
currently, a 2—4 week application is recommended. Be-
cause of the short duration of the treatment and the asso-
ciated time-limited side effects, this regimen is usually well 
tolerated by the patients [51]. However, the sometimes 
very pronounced side effects (severe crusting and hem-
orrhage) after treatment of a large area can be a severe 
limitation. In the 90ies, Plewig and coworkers inaugurated 
a combination therapy with isotretinoin, which included the 
daily application of 5-fu in combination with oral isotreti-
noin 20mg/day for 21 days. The clinical response rates 
were very good, however often severe erosions and hem-
orrhagic crusts appeared which required hospitalization of 
the patients [53].
Photodynamic therapy
for the implementation of field-directed PDT in mild to 
moderate AK, the two photosensitizers 5-aminolevulinic 
acid-methyl ester (MAL) Metvix® and 5-ALA nanoemulsion 
Ameluz® are available. In both cases the 3-hour incubation 
period is followed by the exposure with red light (630 nm, 
37 j/cm2). for PDT with MAL, response rates of 71—91% 
are specified, whereas a better overall effect is achieved 
with thin lesions [34, 54]. clinical trials of the effective-
ness of PDT with the 5-ALA nanoemulsion show response 
rates of 80—91% 12 weeks after therapy [55]. A long-term 
follow-up demonstrated a slightly better outcome for pa-
tients who have been treated with 5-ALA in comparison to 
MAL after 12 weeks, the differences were not significant, 
however [56]. Advantage of PDT is the fact that the treat-
ment — in the sense of an «office-based therapy” — can 
be carried out in one day under complete observation 
and, if necessary, can be repeated indefinitely. Due to the 
field-directed treatment even so far clinically incipient le-
sions are treated. This leads to a reduction of occurrence 
of further AK for a period of 6 months in immunocompe-
tent patients [9, 56, 57]. furthermore, the cosmetic results 
after PDT are excellent. In comparison with cryotherapy, 
PDT showed a much better cosmetical outcome 3 months 
after treatment, which is also reflected by the patient sat-
isfaction [34]. Overall, it appears that PDT in patients with 
sun damaged skin leads to a smoother skin appearance 
with less redness, pigmentation spots and teleangiectases 
[56]. However, in some cases pain during illumination rep-
resents a significant problem. Patients with AK lesions on 
the face and scalp, severe sun damage, fitzpatrick skin 
type I, and male gender are more likely to experience pain 
during illumination. Therefore it may make sense to limit 
the treatment area to smaller size and to perform PDT ses-
sions stepwise in order to ameliorate pain. Also the use of 
cooling during illumination or in large areas the application 
of nerve blocks is advisable [58]. In addition, 1—2 days 
after treatment appear side effects like redness, swelling, 
and pustules and crusts in the treated area [56]. A much 
more gentle procedure is the possibility of the so-called 
natural daylight-PDT (NDL-PDT) in which patients stay for 
a time of 2 hours in the sun 30 minutes after application of 
MAL. first results show similar good response rates for the 
treatment of mild-to-moderate AK by a favorable adverse 
event profile in comparison to the classic red light-PDT 
[59, 60]. just recently, the Australian Therapeutic Goods 
Administration (TGA) has registered MAL in combination 
with daylight for the treatment of AK.
Combination procedures
The application of combination procedures can be use-
ful in cases of refractory AK-lesions. It is also assumed 
that combination procedures with different mechanism of 
action lead to a better long-term effects [61]
first and foremost, there is the implementation of a 
fractional cO2 laser treatment followed by PDT. The pre-
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treatment with a laser or also microneedling results in an 
increased penetration of ALA or MAL, which then leads to 
a higher concentration of protoporphyrin IX in the target tis-
sue, and therefore significantly increases the effectiveness 
of PDT [61, 62]. while in a clinical trial by Togsverd-Bo et 
al. after a single PDT 67% of the lesions were completely 
healed, the response rate of the combined procedure in-
creased to 90% [61]. In addition, there are reports of an 
improved efficacy by a combination treatment of PDT with 
imiquimod 5% [63] or a combination of 5-fluorouracil and 
imiquimod cream [64]. Also the combination of a field-di-
rected treatment followed by a lesion-directed treatment of 
isolated, refractory AK represents a possible option, for ex-
ample the application of diclofenac sodium gel followed by 
a treatment of an 5-fu-containing lacquer for remaining hy-
perkeratotic AK. Even if it would be a matter of a few clinical 
trials with small numbers, it makes sense to apply combina-
tion procedures in profound and refractory cases. Since AK 
is a chronic disease, treatment is conducted with the objec-
tive of a long remission phase. Here the combination proce-
dures also seem to be superior to monotherapies [61—64].
The choice of the therapeutic regime should be ac-
cording to the clinical findings and the needs of the pa-
tient in the first instance. Depending on the occurrence 
of the AK-lesions, it is advisable to start with a lesion- or 
field-directed monotherapy. A final assessment should be 
performed three months after the end of therapy. In case 
of a complete clinical response regular checks are recom-
mended. If an insufficient healing of the lesions is shown 
after a treatment-period of three months despite adequate 
therapy, the treatment should be repeated or replaced by 
another therapy or be added by a combination procedure. 
In case of patients with significantly higher risk of transi-
tion of AK into Scc, control consultation should be more 
frequent..
Conclusion
The main cause of actinic keratoses is chronic uV ex-
posure. The application of a consistent uV-protection (tex-
tile, sun protection products) is therefore essential. Due to 
the risk of transition to Scc in about 6—10% of cases, 
a treatment of AK is recommended. There are numerous 
lesion- and field-directed therapeutic options for the treat-
ment of AK, the recently approved methods have a high 
therapeutic effectiveness following evidence-based cri-
teria. The selection of the suitable therapy should be dis-
cussed with the patient. Because of the chronicity of the 
disease, sometimes a change in the course of the regimen 
can be useful. In refractory cases, or very early recurrenc-
es, a combination therapy could be of help. The patient 
should be informed about the need for a long-term therapy 
and prophylaxis (light protection). In case of clinically indif-
ferent lesions a biopsy is necessary in order to exclude an 
already existing Scc. 
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